Summary

The Global Autoinjector Market is valued at USD 90.6 billion in 2024 growing at a CAGR of 6.2% during the forecast period 2024-2035.

Autoinjectors are self-injection devices inbuilt to deliver a specific dose of a drug / therapeutic substance with a simple push of a button. They are spring-loaded syringes working on several mechanisms (ranging from simple push-on-skin devices to fully automated button activated technologies) and include pre-measured medication, thereby, eliminating the need to draw medication from a separate vial, thus resolving various injection-related compliance issues faced by the patients.
The Global Autoinjectors Market is driven by a growing demand for self-administration devices largely due to the increasing chronic conditions such as asthma, diabetes, multiple sclerosis and rheumatoid arthritis. Moreover, these conditions have also been adding to the increasing healthcare burden. A study conducted in the year 2022 reveals that there are around 133 million individuals suffering from one or more chronic illness within the US alone, wherein the predicted value by 2030, is 177 million. The market insights reveal that the treatment of chronic diseases in the hospitals involves intensive care and costs more than USD 1,500 billion per year with additional expenses throughout an individual’s lifetime. The frequent need to take the medication, necessitating regular hospital visits, contributes to the major share of the expenses incurred by patients suffering from chronic diseases. In addition, the reluctance of individuals to receive injections in a clinical setting due to privacy concerns and discomfort complements the challenges for healthcare providers, compromising the treatment process.
Hence, the above-mentioned challenges are addressed by various self-administering drug delivery systems, such as prefilled syringes, large volume wearable injectors, needle free jet injectors, turning out to be a breakthrough. These drug delivery devices impart greater independence, eliminating the dependence on healthcare providers for drug administration, leading to reduced healthcare costs. However, these drug delivery systems possess certain limitations, such as skin sensitivity issues, manual needle insertion, and needle stick injuries, thereby creating the need for better administration solutions.
Because of the insufficiency of the conventional drug delivery systems, the rapid gaining performance of autoinjectors is worth noticing, specifically in the immediate treatment of emergency situations, such as anaphylactic shocks, strokes and rheumatoid arthritis. In addition, the audio-visual features in some of the autoinjectors allow the patient to remove the device from the skin, on completion of dose. The growing adoption of self-administration devices and ongoing advancements in the technologies (focused on integrated needle safety, Bluetooth connectivity and monitoring of historical injection logs), tends to create a growing market of Autoinjectors henceforth.


Key Market Segments
Usability of Autoinjectors
 Disposable Autoinjector
 Reusable Autoinjector
Route of Administration
 Subcutaneous
 Intramuscular
 Intravenous
Type of Molecule Delivered
 Proteins
 Antibodies
 Peptides
 Small molecules
 Others
Type of Actuation Mechanism
 Manual
 Automatic
Volume of Container
 Less than 1 ml
 1-2 ml
 More than 2 ml
End User
 Home Care
 Hospitals and Clinics
 Ambulatory Surgical Centers
Target Indication
 Rheumatoid Arthritis
 Multiple Sclerosis
 Diabetes
 Weight Loss
 Anaphylaxis
 Migraine
 Others
Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Middle East and North Africa
 Latin America

Research Coverage:
 The chapter gives an overview of various self-administrable devices for drug delivery, specifically focusing on autoinjectors. The chapter provides information on the progression of autoinjectors, along with related details such as, their individual components, device categories and associated manufacturing / packaging processes. It also discusses the advantages of autoinjectors that have led to their growing adoption over the last several years along with the existing concerns related to needlestick injuries and the various preventive laws that have been passed worldwide, for addressing the pressing need for introducing advanced safety features in such devices. In addition, it also includes a discussion on the prospects of this industry.
 The chapter also discusses about the various types of primary drug containers that are utilized in autoinjectors. It demonstrates information on current trends related to the use of prefilled syringes, cartridges and vials. In addition, enlistment the diverse types of primary drug containers that are available in the market, along with details on companies that are involved in the production of such containers is also included in the chapter.
 A thorough analysis of current market landscape of autoinjectors based on several relevant parameters, such as status of development (commercialized and under development), usability (disposable autoinjector and reusable autoinjector), type of primary drug container (cartridges, syringes and vials), requirement of needle, volume of container (less than 1 mL, 1 to 2 mL, 2.1 to 5 mL and more than 5 mL), type of dose delivered (fixed dose and variable dose), route of administration (intramuscular, subcutaneous and unspecified / others), type of actuation mechanism (manual and automatic), type of feedback mechanism (audible and visual), availability of connectivity feature, target indication (diabetes, multiple sclerosis, rheumatoid arthritis and others), type of molecule delivered (antibodies, peptides, proteins, small molecules and others) and end user (home care, hospital and clinics, and others). Further, the chapter provides a comprehensive analytical report of autoinjector manufacturers, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, type of company and most active players (in terms of number of autoinjectors manufactured).
 A cross-examined report comprising the market of autoinjectors based on the manufacturer strength (in terms of years of experience and company size) and product strength (in terms of status of development, type of drug container, requirement of needle, volume of container, type of dose delivered, type of actuation mechanism, type of feedback mechanism, number of target indication and number of molecules delivered).
 The report includes a detailed biopsy of the leading autoinjector manufacturers, highlighting the current perceptions regarding their proprietary brands across different device types. It takes into consideration several aspects, such as strength and diversity of product portfolio, routes of administration, type of actuation mechanism, type of feedback mechanism, geographical presence / reach and supplier strength of each player.
 A comprehensive profile of key autoinjector manufacturers (shortlisted based on the number of autoinjectors in their product portfolio). Each profile attributes a brief overview of the company (including information on year of establishment, location of headquarters, number of employees and leadership team), details related to its financial performance (if available), autoinjectors portfolio, recent developments and an informed future outlook.
 An in-depth analysis of the partnerships inked between stakeholders engaged in this industry, during the period 2019-2023, based on several parameters. These parameters include partnership, type of partnership, type of partner and most active players (in terms of the number of partnerships signed). It also provides for the regional distribution of the companies involved in these agreements.
 The chapter provides a detailed exploration of patents related to autoinjectors, filed / granted, since 2019, based on the type of patent (granted patents, patent applications and others), patent publication year, patent application year, patent jurisdiction, cooperative patent classification (CPC) symbols, type of applicant and most active players (in terms of the number of patents filed). In addition, the chapter includes patent benchmarking and an insightful patent valuation analysis, highlighting the leading patents (in terms of number of citations).
 The chapter provides a detailed overview encompassing current market landscape of commercialized autoinjectors combination product, such as approval year, usability (disposable autoinjector and reusable autoinjector), type of primary drug container (ampoules, cartridges, syringes and vials), requirement of needle, volume of container (less than 0.5 mL, 0.5 to 1 mL and more than 1 mL), injection time (less than 5 seconds, 5 to 10 seconds and more than 10 seconds), type of dose delivered (fixed and variable), route of administration (intramuscular, intravenous and subcutaneous), type of actuation mechanism (automatic, manual and semi-automatic), type of feedback mechanism (audible and visual), availability of connectivity feature, target indication, severity of indication (acute conditions, chronic conditions and emergency conditions), type of molecule delivered (antibodies, peptides, proteins, small molecules and others), end user (home care setting, hospital and clinics, and others) and target population (adults, geriatric and pediatrics). Further, the chapter provides explanation on commercialized autoinjector combination product manufacturers, along with information on establishment year, company size (in terms of employee count), location of headquarters, type of company and most active players (in terms of number of commercialized autoinjector combination products developed).
 The chapter elucidates a detailed progression of the current market landscape of early and late stage autoinjectors combination product, such as stage of development (preclinical, clinical, NDA submitted and NDA approved), route of administration (intramuscular, subcutaneous and unspecified / others), dose strength, target indication, severity of indication (acute conditions, chronic conditions and emergency conditions), type of molecule delivered (antibodies, peptides, proteins, small molecules and others), end user (home care setting and hospital and clinics), target population (adults, geriatric and pediatrics) and gender of target population (male and female). Moreover, the chapter also clarifies details on manufacturers, along with information on year of establishment, company size (in terms of employee count), location of headquarters and type of company.
 Comprehensive set of profiles of the key players (shortlisted based on the number of commercialized combination products in their product portfolio) that are engaged in the autoinjector combination products domain. Each profile provides an insight of the company (including information on year of establishment, location of headquarters, number of employees and leadership team) and information on its autoinjector product portfolio.
 A detailed analyzed evaluation highlighting the key opinion leaders (KOLs) in this domain, based on several relevant factors, such as role of KOL, type of sponsor organization, affiliated organization, target indication and location of clinical trials. In addition, the chapter highlights the most prominent KOLs, based on our proprietary scoring criteria.
 An epitome on the most targeted indications covering detailed explication of the approved autoinjector combination products.
 A case study converged on the role of medical device CMOs in the manufacturing and assembly of drug-delivery devices, including autoinjectors. It enlists service providers with details on their operational scale and types of services provided for device production.
 An intricate case history of prefilled syringes that either fall into the category of commercialized or under development. It includes an itemized description of the prefilled syringes, based on several relevant dynamics, such as, type of barrel fabrication material, number of barrel chambers and type of needle system. Further, the chapter provides a detailed analysis of prefilled syringe manufacturers, along with information on their year of establishment, company size (in terms of employee count) and location of headquarters.
 An enumerated report on industry affiliated trends, opportunities and challenges, under a SWOT analysis, which are likely to impact the evolution of autoinjectors market; it includes a Harvey ball analysis, underlining the relative impact of each SWOT parameter on industry dynamics.
 A substantial report on the autoinjectors market forecast analysis to estimate the existing market size and future opportunity in the market, till the year 2035. Based on multiple parameters, such as likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2024-2035. The report also comprehends the likely distribution of the current and forecasted opportunity within the autoinjector market. Moreover, accounting for future uncertainties and to adding robustness to our model, three forecast scenarios have been provided, namely conservative, base, and optimistic scenarios, targeting different tracks of the industry’s growth.
 An insightful projection of the current and future opportunity within the autoinjectors market across usability, such as disposable autoinjectors and reusable autoinjector.
 Detailed projections of the current and future opportunity within the auto injector market size across several types of dynamics, which include route of administration, such as intramuscular, intravenous and subcutaneous, the type of molecule, such as antibodies, peptides, proteins, small molecules and others, type of actuation mechanism, such as manual and automatic, volume of container, such as less than 1 mL, 1-2 mL and more than 2 mL, various end user, such as ambulatory surgical centers, home care and hospitals and clinics.
 An in-depth insightful projection of the current and future opportunity within the autoinjector market across target indication, such as anaphylaxis, diabetes, migraine, multiple sclerosis, rheumatoid arthritis, weight loss and other indications.
 A comprehensive report carrying details about the projections of the current and future opportunity within the autoinjectors market key across various geographies, such as North America, Europe, Asia-Pacific, Middle East and North Africa and Latin America.
Key Benefits of Buying this Report
 The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
 Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
 The report provides stakeholders with a pulse on the Global Autoinjectors Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Leading Market Companies
 Amgen
 Antares Pharma
 ChemProtect.SK
 Elcam Medical
 Eli Lilly and Company
 Jiangsu Delfu Medical Device
 Kindeva Drug Delivery
 Merck
 Novartis
 Novo Nordisk
 Oval Medical Technologies
 Owen Mumford
 PreciHealth
 Recipharm
 Sanofi
 SHL Medical
 Teva Pharmaceuticals
 Union Medico
 Ypsomed

ページTOPに戻る

Table of Contents

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentation
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Types of Drug Delivery Systems
5.3. Drawbacks of Conventional Parenteral Delivery Systems
5.4. Emerging Trend of Self-Administration
5.4.1. Rising Burden of Chronic Diseases
5.4.2. Healthcare Cost Savings
5.4.3. Need for Immediate Treatment in Emergency Situations
5.4.4. Growth of Injectable Biologics Market
5.4.5. Addressing Key User Safety Requirements
5.5. Types of Self-Administration Devices
5.5.1. Prefilled Syringes
5.5.2. Pen-Injectors
5.5.3. Needle-Free Injectors
5.5.4. Large Volume Wearable Injectors
5.5.5. Autoinjectors
5.6. Overview of Autoinjectors
5.6.1. Components of Autoinjectors
5.6.2. Classification of Autoinjectors
5.6.2.1. Classification Based on Mechanism of Action
5.6.2.2. Classification Based on Usability
5.6.2.3. Classification Based on Type of Dose Delivered
5.6.3. Manufacturing / Packaging of Autoinjectors
5.6.4. Benefits of Autoinjectors
5.7. Regulatory Considerations
5.7.1. Medical Devices
5.7.2. Drug Device Combination Products
5.8. Future Perspectives
6. PRIMARY DRUG CONTAINERS USED IN AUTOINJECTORS
6.1. Chapter Overview
6.2. Types of Packaging
6.3. Primary Drug Containers
6.3.1. Role of Primary Drug Containers
6.3.2. Cartridges
6.3.2.1. Components of Cartridges
6.3.2.2. Types of Cartridges
6.3.2.2.1. Single Chamber Cartridge
6.3.2.2.2. Dual Chamber Cartridge
6.3.2.3. Commercially Available Cartridges
6.3.3. Syringes
6.3.3.1. Components of Syringes
6.3.3.2. Classification of Syringes
6.3.3.2.1. Classification Based on Barrel Fabrication Material
6.3.3.2.2. Classification Based on Number of Chambers in the Barrel
6.3.3.2.3. Classification Based on Type of Needle
6.3.4. Vials
6.3.4.1. Components of Vials
6.3.4.2. Commercially Available Vials
6.4. Comparison of Different Fabrication Materials
7. AUTOINJECTORS: MARKET OVERVIEW
7.1. Chapter Overview
7.2. Autoinjectors: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Usability
7.2.3. Analysis by Type of Primary Drug Container
7.2.4. Analysis by Requirement of Needle
7.2.5. Analysis by Volume of Container
7.2.6. Analysis by Type of Dose Delivered
7.2.7. Analysis by Route of Administration
7.2.8. Analysis by Type of Actuation Mechanism
7.2.9. Analysis by Type of Feedback Mechanism
7.2.10. Analysis by Availability of Connectivity Feature
7.2.11. Analysis by Target Indication
7.2.12. Analysis by Type of Molecule Delivered
7.2.13. Analysis by End-user
7.3. Autoinjector Manufacturers: Overall Market Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters
7.3.4. Analysis by Company Size and Location of Headquarters
7.3.5. Analysis by Type of Company
7.3.6. Most Active Players: Analysis by Number of Autoinjectors
8. PRODUCT COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Autoinjectors: Product Competitiveness Analysis
8.4.1. Disposable Autoinjectors
8.4.2. Reusable Autoinjectors
9. BRAND POSITIONING ANALYSIS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. Autoinjector Manufacturers: Brand Positioning Framework
9.4.1. Brand Positioning Framework: Owen Mumford
9.4.2. Brand Positioning Framework: Ypsomed
9.4.3. Brand Positioning Framework: Elcam Medical
9.4.4. Brand Positioning Framework: SHL Medical
9.4.5. Brand Positioning Framework: Union Medico
9.4.6. Brand Positioning Framework: Antares Pharma
9.4.7. Brand Positioning Framework: PreciHealth
9.4.8. Brand Positioning Framework: Jiangsu Delfu Medical Device
9.4.9. Brand Positioning Framework: Oval Medical Technologies
9.4.10. Brand Positioning Framework: Recipharm

10. AUTOINJECTOR MANUFACTURERS: DETAILED COMPANY PROFILES
10.1. Chapter Overview
10.2. Antares Pharma
10.2.1. Company Overview
10.2.2. Financial Information
10.2.3. Autoinjectors Portfolio
10.2.4 Recent Developments and Future Outlook
10.3. Elcam Medical
10.3.1. Company Overview
10.3.2. Autoinjectors Portfolio
10.3.3. Recent Developments and Future Outlook
10.4. Jiangsu Delfu Medical Device
10.4.1. Company Overview
10.4.2. Autoinjectors Portfolio
10.4.3. Recent Developments and Future Outlook
10.5. Oval Medical Technologies
10.5.1. Company Overview
10.5.2. Autoinjectors Portfolio
10.5.3. Recent Developments and Future Outlook
10.6. Owen Mumford
10.6.1. Company Overview
10.6.2. Autoinjectors Portfolio
10.6.3. Recent Developments and Future Outlook
10.7. PreciHealth
10.7.1. Company Overview
10.7.2. Autoinjectors Portfolio
10.7.3. Recent Developments and Future Outlook
10.8. Recipharm
10.8.1. Company Overview
10.8.2. Financial Information
10.8.3. Autoinjectors Portfolio
10.8.4. Recent Developments and Future Outlook
10.9. SHL Medical
10.9.1. Company Overview
10.9.2. Autoinjectors Portfolio
10.9.3. Recent Developments and Future Outlook
10.10. Union Medico
10.10.1. Company Overview
10.10.2. Autoinjectors Portfolio
10.10.3. Recent Developments and Future Outlook
10.11. Ypsomed
10.11.1. Company Overview
10.11.2. Financial Information
10.11.3. Autoinjectors Portfolio
10.11.4. Recent Developments and Future Outlook
10.3. Recent Expansion Models
10.3.1. Expansion Models
10.3.2 List of Recent Expansions
10.3.3. Analysis by Year of Expansion
10.3.4. Analysis by Type of Expansion
10.3.5. Analysis by Year and Type of Expansion
10.3.6. Analysis by Location of Expanded Facility (Region)
10.3.7. Analysis by Location of Expanded Facility (Country)
10.3.8. Recent Expansions: Analysis by Location of Expanded Facility and Type of Expansion
10.3.9. Most Active Players: Analysis by Number of Expansions
10.3.10. Recent Expansions: Analysis by Geography (Country)
10.3.11. Recent Expansions: List of Planned Expansions
10.4. Emerging Peptide Synthesis Technologies
10.4.1. Chemo-Enzymatic Peptide Synthesis Technology
10.4.2. Continuous Flow Technology
10.4.3. Green Chemistry
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. Autoinjectors: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Type of Product
11.3.5. Analysis by Type of Partner
11.3.6. Most Active Players: Analysis by Number of Partnerships
11.3.7. Analysis by Geography
11.3.7.1. Intracontinental and Intercontinental Deals
11.3.7.2. International and Local Deals
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Autoinjectors: Patent Analysis
12.3.1. Analysis by Patent Publication Year
12.3.2. Analysis by Type of Patent and Patent Publication Year
12.3.3. Analysis by Patent Application Year
12.3.4. Analysis by Patent Jurisdiction
12.3.5. Analysis by CPC Symbols
12.3.6. Analysis by Type of Applicant
12.3.7. Leading Industry Players: Analysis by Number of Patents
12.3.8. Leading Individual Assignees: Analysis by Number of Patents
12.4. Patent Benchmarking Analysis
12.4.1. Analysis By Patent Characteristics
12.5. Patent Valuation
12.6. Leading Patents by Number of Citations
13. DEMAND ANALYSIS DRUG DEVICE COMBINATIONS: COMMERCIALIZED AUTOINJECTORS
13.1. Chapter Overview
13.2. Drug Device Combinations: Commercialized Autoinjectors
13.2.1. Analysis by Approval Year
13.2.2. Analysis by Usability
13.2.3. Analysis by Type of Primary Drug Container
13.2.4. Analysis by Requirement of Needle
13.2.5. Analysis by Volume of Container
13.2.6. Analysis by Injection Time
13.2.7. Analysis by Type of Dose Delivered
13.2.8. Analysis by Route of Administration
13.2.9. Analysis by Type of Actuation Mechanism
13.2.10. Analysis by Type of Feedback Mechanism
13.2.11. Analysis by Availability of Connectivity Feature
13.2.12. Analysis by Target Indication
13.2.13. Analysis by Severity of Indication
13.2.14. Analysis by Type of Molecule Delivered
13.2.15. Analysis by End-user
13.2.16. Analysis by Target Population
13.3. Drug Device Combinations: Commercialized Autoinjector Developers
13.3.1. Analysis by Year of Establishment
13.3.2. Analysis by Company Size
13.3.3. Analysis by Location of Headquarters
13.3.4. Analysis by Company Size and Location of Headquarters
13.3.5. Analysis by Type of Company
13.3.6. Most Active Players: Analysis by Number of Commercialized Autoinjector Combination Products
14. DRUG DEVICE COMBINATIONS: EARLY AND LATE STAGE AUTOINJECTORS
14.1. Chapter Overview
14.2. Drug Device Combinations: Early and Late Stage Autoinjectors
14.2.1. Analysis by Stage of Development
14.2.2. Analysis by Route of Administration
14.2.3. Analysis by Dose Strength
14.2.4. Analysis by Target Indication
14.2.5. Analysis by Severity of Indication
14.2.6. Analysis by Type of Molecule Delivered
14.2.7. Analysis by End-user
14.2.8. Analysis by Target Population
14.2.9. Analysis by Gender of Target Population
14.3. Drug Device Combinations: Early and Late Stage Autoinjector Developers Landscape
14.3.1. Analysis by Year of Establishment
14.3.2. Analysis by Company Size
14.3.3. Analysis by Location of Headquarters
14.3.4. Analysis by Company Size and Location of Headquarters
14.3.5. Analysis by Type of Company
15. SHORT COMPANY PROFILES: AUTOINJECTOR COMBINATION PRODUCT DEVELOPERS
15.1. Chapter Overview
15.2. Amgen
15.2.1. Company Overview
15.2.2. Autoinjector Combination Product Portfolio
15.3. ChemProtect.SK
15.3.1. Company Overview
15.3.2. Autoinjector Combination Product Portfolio
15.4. Eli Lilly and Company
15.4.1. Company Overview
15.4.2. Autoinjector Combination Product Portfolio
15.5. Kindeva Drug Delivery
15.5.1. Company Overview
15.5.2. Autoinjector Combination Product Portfolio
15.6. Merck
15.6.1. Company Overview
15.6.2. Autoinjector Combination Product Portfolio
15.7. Novartis
15.7.1. Company Overview
15.7.2. Autoinjector Combination Product Portfolio
15.8. Novo Nordisk
15.8.1. Company Overview
15.8.2. Autoinjector Combination Product Portfolio
15.9. Sanofi
15.9.1. Company Overview
15.9.2. Autoinjector Combination Product Portfolio
15.10. Teva Pharmaceutical Industries
15.10.1. Company Overview
15.10.2. Autoinjector Combination Product Portfolio
16. KEY OPINION LEADER ANALYSIS
16.1. Chapter Overview
16.2. Assumption and Key Parameters
16.3. Methodology
16.4. Autoinjectors: Key Opinion Leaders
16.4.1. Analysis by Role of KOL
16.4.2. Analysis by Type of Sponsor Organization
16.4.3. Analysis by Affiliated Organization
16.4.4. Analysis by Target Indication
16.4.5. Analysis by Location of Clinical Trials
16.4.6 Most Prominent KOLs: Analysis by Activeness, Expertise and Strength of KOL
16.4.7. Most Prominent KOLs: Analysis by Roots Analysis Score

17. CASE STUDY: KEY THERAPEUTIC INDICATIONS
17.1. Chapter Overview
17.2. Anaphylaxis
17.2.1. Overview and Epidemiology
17.2.2. Treatment for Anaphylaxis
17.2.3. Autoinjectors for Anaphylaxis
17.3. Multiple Sclerosis
17.3.1. Overview and Epidemiology
17.3.2. Treatment for Multiple Sclerosis
17.3.3. Autoinjectors for Multiple Sclerosis
17.4. Migraine
17.4.1. Overview and Epidemiology
17.4.2. Treatment for Migraine
17.4.3. Autoinjectors for Migraine
17.5. Rheumatoid Arthritis
17.5.1. Overview and Epidemiology
17.5.2. Treatment for Rheumatoid Arthritis
17.5.3. Autoinjectors for Rheumatoid Arthritis
18. CASE STUDY: MEDICAL DEVICE CONTRACT SERVICE PROVIDERS
18.1. Chapter Overview
18.2. Challenges Associated with Medical Device Manufacturing
18.3. Role of CMOs in Medical Device Manufacturing
18.4. Services Offered by Medical Device CMOs
18.5. Advantages Offered by Medical Device CMOs
18.6. Risks Associated with Outsourcing to CMOs
18.7. Drug Delivery Device Service Providers
18.7.1. Analysis by Year of Establishment
18.7.2. Analysis by Company Size
18.7.3. Analysis by Location of Headquarters
18.7.4. Analysis by Type of Services
18.8. Concluding Remarks
19. CASE STUDY: PREFILLED SYRINGES
19.1. Chapter Overview
19.2. Prefilled Syringes: Market Landscape
19.2.1. Analysis by Type of Barrel Fabrication Material
19.2.2. Analysis by Number of Barrel Chambers
19.2.3. Analysis by Type of Needle System
19.3. Prefilled Syringes Manufacturers: Overall Market Landscape
19.3.1. Analysis by Year of Establishment
19.3.2. Analysis by Company Size
19.3.3. Analysis by Location of Headquarters
19.4. Future Perspectives
20. SWOT ANALYSIS
20.1. Chapter Overview
20.2. Strengths
20.2.1. Ease of Drug Delivery
20.2.2. Ability to Minimize / Eliminate Medication Errors
20.2.3. Enhanced Safety Features
20.2.4. Economic Advantages
20.2.5. Drug Life Cycle Management
20.3. Weaknesses
20.3.1. Manufacturing Complexities
20.3.2. Customized Design for Different Formulations
20.3.3. Use Errors
20.3.4. Stringent Regulatory Guidelines
20.4. Opportunities
20.4.1. Rich and Growing Pipeline of Biologics and Biosimilars
20.4.2. Growing Preference for Self-Injection Devices
20.4.3. Integration of Advanced Technologies
20.4.4. Rising Popularity across the Globe
20.5. Threats
20.5.1. Material Compatibility Issues
20.5.2. Availability of Alternative Drug Delivery Devices
20.5.3. Concern Related to Numerous Product Recalls In Past
20.6. Concluding Remarks
21. GLOBAL AUTOINJECTORS MARKET
21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Global Autoinjectors Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
21.3.1. Scenario Analysis
21.3.1.1. Conservative Scenario
21.3.1.2 Optimistic Scenario
21.4. Key Market Segmentations
22. AUTOINJECTORS MARKET, BY USABILITY
22.1. Chapter Overview
22.2. Assumptions and Methodology
22.3. Autoinjectors Market: Distribution by Usability, 2018, 2024 and 2035
22.3.1. Disposable Autoinjectors Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.3.2. Reusable Autoinjectors Market: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
22.4. Data Triangulation and Validation
23. AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION24. EXECUTIVE INSIGHTS
23.1. Chapter Overview
23.2. Assumptions and Methodology
23.3. Autoinjectors Market: Distribution by Route of Administration, 2018, 2024 and 2035
23.3.1. Autoinjectors Market for Subcutaneous Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
23.3.2. Autoinjectors Market for Subcutaneous / Intramuscular Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
23.3.3. Autoinjectors Market for Subcutaneous / Intravenous Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
23.3.4. Autoinjectors Market for Intramuscular Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
23.3.5. Autoinjectors Market for Intravenous Administration: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
23.4. Data Triangulation and Validation
24. AUTOINJECTORS MARKET, BY TYPE OF MOLECULE DELIVERED
24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Autoinjectors Market: Distribution by Type of Molecule Delivered, 2018, 2024 and 2035
24.3.1. Autoinjectors Market for Proteins: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
24.3.2. Autoinjectors Market for Small Molecules: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
24.3.3. Autoinjectors Market for Antibodies: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
24.3.4. Autoinjectors Market for Peptides: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
24.3.5. Autoinjectors Market for Other Molecules: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
24.4. Data Triangulation and Validation
25. AUTOINJECTORS MARKET, BY TYPE OF ACTUTATION MECHANISM
25.1. Chapter Overview
25.2. Assumptions and Methodology
25.3. Autoinjectors Market: Distribution by Type of Actuation Mechanism, 2018, 2024 and 2035
25.3.1. Autoinjectors Market for Automatic Actuation: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
25.3.2. Autoinjectors Market for Manual Actuation: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
26. AUTOINJECTORS MARKET, BY VOLUME OF CONTAINER
26.1. Chapter Overview
26.2. Assumptions and Methodology
26.3. Autoinjectors Market: Distribution by Volume of Container, 2018, 2024 and 2035
26.3.1. Autoinjectors Market for Less than 1 mL Volume: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
26.3.2. Autoinjectors Market for 1- 2 mL Volume: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
26.3.3. Autoinjectors Market for More than 2 mL Volume: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
27. AUTOINJECTORS, BY END-USER
27.1. Chapter Overview
27.2. Assumptions and Methodology
27.3. Autoinjectors Market: Distribution by End-user, 2018, 2024 and 2035
27.3.1. Autoinjectors Market for Home Settings: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
27.3.2. Autoinjectors Market for Hospitals and Clinics: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
27.3.3. Autoinjectors Market for Ambulatory Surgical Centers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
27.4. Data Triangulation and Validation
28. AUTOINJECTORS MARKET, BY TARGET INDICATION
28.1. Chapter Overview
28.2. Assumptions and Methodology
28.3. Autoinjectors Market: Distribution by Target Indication, 2018, 2024 and 2035
28.3.1. Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
28.3.2. Autoinjectors Market for Multiple Sclerosis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
28.3.3 Autoinjectors Market for Diabetes: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) Data Triangulation
28.3.4. Autoinjectors Market for Anaphylaxis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
28.3.5. Autoinjectors Market for Weight Loss: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
28.3.6. Autoinjectors Market for Migraine: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
28.3.7. Autoinjectors Market for Other Indications: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
28.4. Data Triangulation and Validation
29. AUTOINJECTORS, BY KEY GEOGRAPHICAL REGION
29.1. Chapter Overview
29.2. Assumptions and Methodology
29.3. Autoinjectors Market: Distribution by Key Geographical Region, 2018, 2024 and 2035
29.3.1. Autoinjectors Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
29.3.2. Autoinjectors Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
29.3.3. Autoinjectors Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
29.3.4. Autoinjectors Market in Middle East and North Africa: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
29.3.4. Autoinjectors Market in Latin America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
29.4. Data Triangulation and Validation
30. AUTOINJECTORS MARKET, FOR RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS
30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis: Distribution by Usability
30.3.1. Disposable Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.3.2. Reusable Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.4. Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis: Distribution by Route of Administration
30.4.1. Subcutaneous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.4.2. Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.4.3. Intravenous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.5. Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis: Distribution by Type of Molecule Delivered
30.5.1. Proteins Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.5.2. Antibodies Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
30.5.3. Small Molecules Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
31. AUTOINJECTORS MARKET, FOR MULTIPLE SCLEROSIS
31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Autoinjectors Market for Multiple Sclerosis: Distribution by Usability
31.3.1. Disposable Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
31.3.2. Reusable Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
31.4. Autoinjectors Market for Multiple Sclerosis: Distribution by Route of Administration
31.4.1. Subcutaneous Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
31.4.2. Intramuscular Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
31.5. Autoinjectors Market for Multiple Sclerosis: Distribution by Type of Molecule Delivered
31.5.1. Proteins Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
31.5.2. Peptides Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
31.5.3. Antibodies Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
32. AUTOINJECTORS MARKET, FOR DIABETES
32.1. Chapter Overview
32.2. Key Assumptions and Methodology
32.3. Autoinjectors Market for Diabetes: Distribution by Usability
32.3.1. Disposable Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
32.3.2. Reusable Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
32.4. Autoinjectors Market for Diabetes: Distribution by Route of Administration
32.4.1. Subcutaneous Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
32.5. Autoinjectors Market for Diabetes: Distribution by Type of Molecule Delivered
32.5.1. Proteins Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
32.5.2. Antibodies Autoinjectors Market for Diabetes, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
33. AUTOINJECTORS MARKET, FOR ANAPHYLAXIS
33.1. Chapter Overview
33.2. Key Assumptions and Methodology
33.3. Autoinjectors Market for Anaphylaxis: Distribution by Usability
33.3.1. Disposable Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
33.4. Autoinjectors Market for Anaphylaxis: Distribution by Route of Administration
33.4.1. Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
33.4.2. Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
33.5. Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule Delivered
33.5.1. Small Molecules Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
34. AUTOINJECTORS MARKET, FOR WEIGHT LOSS
34.1. Chapter Overview
34.2. Key Assumptions and Methodology
34.3. Autoinjectors Market for Weight Loss: Distribution by Usability
34.3.1. Disposable Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
34.4. Autoinjectors Market for Weight Loss: Distribution by Route of Administration
34.4.1. Subcutaneous Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
34.5. Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule Delivered
34.5.1. Peptides Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
34.5.2. Small Molecules Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
35. AUTOINJECTORS MARKET, FOR MIGRAINE
35.1. Chapter Overview
35.2. Key Assumptions and Methodology
35.3. Autoinjectors Market for Migraine: Distribution by Usability
35.3.1. Disposable Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
35.4. Autoinjectors Market for Migraine: Distribution by Route of Administration
35.4.1. Subcutaneous Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
35.5. Autoinjectors Market for Migraine: Distribution by Type of Molecule Delivered
35.5.1. Antibodies Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
35.5.2. Proteins Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
35.5.3. Small Molecules Autoinjectors Market for Migraine, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36. AUTOINJECTORS MARKET, FOR OTHER INDICATIONS
36.1. Chapter Overview
36.2. Key Assumptions and Methodology
36.3. Autoinjectors Market for Other Indications: Distribution by Usability
36.3.1. Disposable Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.3.2. Reusable Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.4. Autoinjectors Market for Other Indications: Distribution by Route of Administration
36.4.1. Subcutaneous Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.4.2. Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.4.3. Subcutaneous / Intravenous Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.5. Autoinjectors Market for Other Indications: Distribution by Type of Molecule Delivered
36.5.1. Antibodies Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.5.2. Proteins Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.5.3. Small Molecules Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
36.5.4. Other Molecules Autoinjectors Market for Other Indications, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035)
37. CONCLUDING REMARKS
38. EXECUTIVE INSIGHTS
38.2. Aktiv Pharma
38.2.1. Company Snapshot
38.2.2. Interview Transcript
38.3. Rx Bandz
38.3.1. Company Snapshot
38.3.2. Interview Transcript
38.4. Kindeva Drug Delivery
38.4.1. Company Snapshot
38.4.2. Interview Transcript
38.5. DALI Medical Devices
38.5.1. Company Snapshot
38.5.2. Interview Transcript:
38.6. Elcam Medical
38.6.1. Company Snapshot
38.6.2. Interview Transcript
38.7. Pharma Consult
38.7.1. Company Snapshot
38.7.2. Interview Transcript
38.8. IDEO
38.8.1. Company Snapshot
38.8.2. Interview Transcript
38.9. Bill & Melinda Gates Foundation
38.9.1. Company Snapshot
38.9.2. Interview Transcript
38.10. Oval Medical Technologies
38.10.1. Company Snapshot
38.10.2. Interview Transcript
38.11. Anonymous
38.12. Anonymous
38.13. Anonymous
38.14. Anonymous
39. APPENDIX 1: TABULATED DATA
40. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

ページTOPに戻る

List of Tables/Graphs

Table 5.1 Comparison of Self-Injection Devices
Table 5.2 Benefits of Autoinjectors
Table 6.1 Commercially Available Cartridges
Table 6.2 Classification of Syringes
Table 6.3 Commercially Available Glass Syringes
Table 6.4 Commercially Available Plastic Syringes
Table 6.5 Commercially Available Vials
Table 6.6 Comparison of Fabrication Material Used for Primary Drug Containers
Table 7.1 Autoinjectors: Overall Market Landscape
Table 7.2 Autoinjectors: Information on Requirement of Needle, Volume of Container, Type of Dose Delivered and Route of Administration
Table 7.3 Autoinjectors: Information on Type of Actuation Mechanism, Type of Feedback Mechanism, Availability of Connectivity Feature and Target Indication
Table 7.4 Autoinjectors: Information on Type of Molecule Delivered and End-user
Table 7.5 Autoinjector Manufacturers: Overall Market Landscape
Table 10.1 Autoinjector Manufacturers: List of Companies Profiled
Table 10.2 Antares Pharma: Company Snapshot
Table 10.3 Antares Pharma: Autoinjectors Portfolio
Table 10.4 Halozyme (Parent Company of Antares Pharma): Recent Developments and Future Outlook
Table 10.5 Elcam Medical: Company Snapshot
Table 10.6 Elcam Medical: Autoinjectors Portfolio
Table 10.7 Jiangsu Delfu Medical Device: Company Snapshot
Table 10.8 Jiangsu Delfu Medical Device: Autoinjectors Portfolio
Table 10.9 Oval Medical Technologies: Company Snapshot
Table 10.10 Oval Medical Technologies: Autoinjectors Portfolio
Table 10.11 Oval Medical Technologies: Recent Developments and Future Outlook
Table 10.12 Owen Mumford: Company Snapshot
Table 10.13 Owen Mumford: Autoinjectors Portfolio
Table 10.14 Owen Mumford: Recent Developments and Future Outlook
Table 10.15 PreciHealth: Company Snapshot
Table 10.16 PreciHealth: Autoinjectors Portfolio
Table 10.17 PreciHealth: Recent Developments and Future Outlook
Table 10.18 Recipharm: Company Snapshot
Table 10.19 Recipharm: Autoinjectors Portfolio
Table 10.20 Recipharm: Recent Developments and Future Outlook
Table 10.21 SHL Medical: Company Snapshot
Table 10.22 SHL Medical: Autoinjectors Portfolio
Table 10.23 SHL Medical: Recent Developments and Future Outlook
Table 10.24 Union Medico: Company Snapshot
Table 10.25 Union Medico: Autoinjectors Portfolio
Table 10.26 Ypsomed: Company Snapshot
Table 10.27 Ypsomed: Autoinjectors Portfolio
Table 10.28 Ypsomed: Recent Developments and Future Outlook
Table 11.1 Autoinjectors: List of Partnerships and Collaborations, 2016-2024
Table 12.1 Patent Analysis: Top CPC Sections
Table 12.2 Patent Analysis: Top CPC Symbols
Table 12.3 Patent Analysis: Top CPC Codes
Table 12.4 Patent Analysis: Summary of Benchmarking Analysis
Table 12.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 12.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 13.1 Drug Device Combinations: Commercialized Autoinjectors
Table 13.2 Commercialized Autoinjector Combination Products: Information on Requirement of Needle, Volume of Container, Injection Time and Type of Dose Delivered
Table 13.3 Commercialized Autoinjector Combination Products: Information on Route of Administration, Type of Actuation Mechanism, Type of Feedback Mechanism and Availability of Connectivity
Table 13.4 Commercialized Autoinjector Combination Products: Information on Target Therapeutic Indication and Severity Of Indication
Table 13.5 Commercialized Autoinjector Combination Products: Information on Type of Molecule Delivered, End-user and Target Population
Table 13.6 Commercialized Autoinjector Combination Products: List of Developers
Table 14.1 Drug Device Combinations: Early and Late Stage Autoinjectors
Table 14.2 Early and Late Stage Autoinjector Combination Products: Information on Dose Strength, Target Indication and Severity of Indication
Table 14.3 Early and Late Stage Autoinjector Combination Products: Information on Type of Molecule Delivered and End-user
Table 14.4 Early and Late Stage Autoinjector Combination Products: Information on Target Population and Gender of Target Population
Table 14.5 Early and Late Stage Autoinjector Combination Products: List of Developers
Table 15.1 Autoinjector Combination Products Developers: List of Companies Profiled
Table 15.2 Amgen: Company Snapshot
Table 15.3 Amgen: Autoinjector Combination Product Portfolio
Table 15.4 ChemProtect.SK: Company Snapshot
Table 15.5 ChemProtect.SK: Autoinjector Combination Product Portfolio
Table 15.6 Eli Lilly and Company: Company Snapshot
Table 15.7 Eli Lilly and Company: Autoinjector Combination Product Portfolio
Table 15.8 Kindeva Drug Delivery: Company Snapshot
Table 15.9 Kindeva Drug Delivery: Autoinjector Combination Product Portfolio
Table 15.10 Merck: Company Snapshot
Table 15.11 Merck: Autoinjector Combination Product Portfolio
Table 15.12 Novartis: Company Snapshot
Table 15.13 Novartis: Autoinjector Combination Product Portfolio
Table 15.14 Novo Nordisk: Company Snapshot
Table 15.15 Novo Nordisk: Autoinjector Combination Product Portfolio
Table 15.16 Sanofi: Company Snapshot
Table 15.17 Sanofi: Autoinjector Combination Product Portfolio2242
Table 15.18 Teva Pharmaceutical Industries: Company Snapshot
Table 15.19 Teva Pharmaceutical Industries: Autoinjector Combination Product Portfolio
Table 16.1 Autoinjectors: List of Key Opinion Leaders
Table 17.1 Anaphylaxis: Commercially Available Autoinjector Combination Products
Table 17.2 Multiple Sclerosis: Commercially Available Autoinjector Combination Products
Table 17.3 Migraine: Commercially Available Autoinjector Combination Products
Table 17.4 Rheumatoid Arthritis: Commercially Available Autoinjector Combination Products
Table 18.1 List of Medical Device CMOs Offering Services for Drug Delivery Devices
Table 18.2 Medical Device CMOs Offering Services for Drug Delivery Devices: Information on Production Services
Table 19.1 Prefilled Syringes: List of Products
Table 19.2 Prefilled Syringes: List of Manufacturers
Table 39.1 Autoinjectors: Distribution by Stage of Development
Table 39.2 Autoinjectors: Distribution by Usability
Table 39.3 Autoinjectors: Distribution by Type of Primary Drug Container
Table 39.4 Autoinjectors: Distribution by Requirement of Needle
Table 39.5 Autoinjectors: Distribution by Volume of Container
Table 39.6 Autoinjectors: Distribution by Type of Dose Delivered
Table 39.7 Autoinjectors: Distribution by Route of Administration
Table 39.8 Autoinjectors: Distribution by Type of Actuation Mechanism
Table 39.9 Autoinjectors: Distribution by Type of Feedback Mechanism
Table 39.10 Autoinjectors: Distribution by Availability of Connectivity Feature
Table 39.11 Autoinjectors: Distribution by Target Indication
Table 39.12 Autoinjectors: Distribution by Type of Molecule Delivered
Table 39.13 Autoinjectors: Distribution by End-user
Table 39.14 Autoinjector Manufacturers: Distribution by Year of Establishment
Table 39.15 Autoinjector Manufacturers: Distribution by Company Size
Table 39.16 Autoinjector Manufacturers: Distribution by Location of Headquarters (Region)
Table 39.17 Autoinjector Manufacturers: Distribution by Location of Headquarters (Country)
Table 39.18 Autoinjector Manufacturers: Distribution by Company Size and Location of Headquarters
Table 39.19 Autoinjector Manufacturers: Distribution by Type of Company
Table 39.20 Most Active Players: Distribution by Number of Autoinjectors
Table 39.21 Antares Pharma: Annual Revenues, FY 2017-FY 2021 (USD Billion)
Table 39.22 Recipharm: Annual Revenues, FY 2018-FY 2022 (SEK Billion)
Table 39.23 Ypsomed: Annual Revenues, FY 2018-H1 FY 2023 (CHF Billion)
Table 39.24 Partnerships and Collaborations: Cumulative Year-wise Trend, 2019-2024
Table 39.25 Partnerships and Collaborations: Distribution by Type of Partnership
Table 39.26 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 39.27 Partnerships and Collaborations: Distribution by Type of Product
Table 39.28 Partnerships and Collaborations: Distribution by Type of Partner
Table 39.29 Most Active Players: Distribution by Number of Partnerships
Table 39.30 Partnerships and Collaborations: Intracontinental and Intercontinental Deals
Table 39.31 Partnerships and Collaborations: International and Local Deals
Table 39.32 Patent Analysis: Distribution by Type of Patent
Table 39.33 Patent Analysis: Distribution by Patent Publication Year, 2019-2023
Table 39.34 Patent Analysis: Distribution by Type of Patent and Publication Year
Table 39.35 Patent Analysis: Distribution by Patent Application Year, Pre-2014-2023
Table 39.36 Patent Analysis: Distribution by Patent Jurisdiction
Table 39.37 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant, 2019-2023
Table 39.38 Leading Industry Players: Distribution by Number of Patents
Table 39.39 Leading Individual Assignees: Distribution by Number of Patents
Table 39.40 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (Top CPC Codes)
Table 39.41 Patent Analysis: Distribution by Patent Age
Table 39.42 Patent Analysis: Patent Valuation
Table 39.43 Commercialized Autoinjector Combination Products: Distribution by Approval Year
Table 39.44 Commercialized Autoinjector Combination Products: Distribution by Usability
Table 39.45 Commercialized Autoinjector Combination Products: Distribution by Type of Primary Drug Container
Table 39.46 Commercialized Autoinjector Combination Products: Distribution by Requirement of Needle
Table 39.47 Commercialized Autoinjector Combination Products: Distribution by Volume of Container
Table 39.48 Commercialized Autoinjector Combination Products: Distribution by Injection Time
Table 39.49 Commercialized Autoinjector Combination Products: Distribution by Type of Dose Delivered
Table 39.50 Commercialized Autoinjector Combination Products: Distribution by Route of Administration
Table 39.51 Commercialized Autoinjector Combination Products: Distribution by Type of Actuation Mechanism
Table 39.52 Commercialized Autoinjector Combination Products: Distribution by Type of Feedback Mechanism
Table 39.53 Commercialized Autoinjector Combination Products: Distribution by Availability of Connectivity Feature
Table 39.54 Commercialized Autoinjector Combination Products: Distribution by Target Indication
Table 39.55 Commercialized Autoinjector Combination Products: Distribution by Severity of Indication
Table 39.56 Commercialized Autoinjector Combination Products: Distribution by Type of Molecule Delivered
Table 39.57 Commercialized Autoinjector Combination Products: Distribution by End-user
Table 39.58 Commercialized Autoinjector Combination Products: Distribution by Target Population
Table 39.59 Commercialized Autoinjector Combination Product Developers: Distribution by Year of Establishment
Table 39.60 Commercialized Autoinjector Combination Product Developers: Distribution by Company Size
Table 39.61 Commercialized Autoinjector Combination Product Developers: Distribution by Location of Headquarters (Region)
Table 39.62 Commercialized Autoinjector Combination Product Developers: Distribution by Location of Headquarters (Country)
Table 39.63 Commercialized Autoinjector Combination Product Developers: Distribution by Company Size and Location of Headquarters
Table 39.64 Commercialized Autoinjector Combination Product Developers: Distribution by Type of Company
Table 39.65 Most Active Players: Distribution by Number of Commercialized Autoinjector Combination Products
Table 39.66 Early and Late Stage Autoinjector Combination Products: Distribution by Stage of Development
Table 39.67 Early and Late Stage Autoinjector Combination Products: Distribution by Route of Administration
Table 39.68 Early and Late Stage Autoinjector Combination Products: Distribution by Dose Strength
Table 39.69 Early and Late Stage Autoinjector Combination Products: Distribution by Target Indication
Table 39.70 Early and Late Stage Autoinjector Combination Products: Distribution by Severity of Indication
Table 39.71 Early and Late Stage Autoinjector Combination Products: Distribution by Type of Molecule Delivered
Table 39.72 Early and Late Stage Autoinjector Combination Products: Distribution by End-user
Table 39.73 Early and Late Stage Autoinjector Combination Products: Distribution by Target Population
Table 39.74 Early and Late Stage Autoinjector Combination Products: Distribution by Gender of Target Population
Table 39.75 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Year of Establishment
Table 39.76 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Company Size
Table 39.77 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Location of Headquarters
Table 39.78 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Company Size and Location of Headquarters
Table 39.79 Early and Late Stage Autoinjector Combination Product Developers: Distribution by Type of Company
Table 39.80 Autoinjectors KOL Analysis: Distribution by Role of KOLs
Table 39.81 Autoinjectors KOL Analysis: Distribution by Type of Sponsor Organization
Table 39.82 Autoinjectors KOL Analysis: Distribution by Affiliated Organization
Table 39.83 Autoinjectors KOL Analysis: Distribution by Target Indication
Table 39.84 Autoinjectors KOL Analysis: Distribution by Location of Clinical Trials
Table 39.85 Autoinjectors Most Prominent KOLs: Distribution by Roots Analysis Score
Table 39.86 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Year of Establishment
Table 39.87 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Company Size
Table 39.88 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Location of Headquarters
Table 39.89 Medical Device CMOs Offering Services for Drug Delivery Devices: Distribution by Types of Services
Table 39.90 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Table 39.91 Prefilled Syringes: Distribution by Number of Barrel Chambers
Table 39.92 Prefilled Syringes: Distribution by Type of Needle System
Table 39.93 Prefilled Syringe Manufacturers: Distribution by Year of Establishment
Table 39.94 Prefilled Syringe Manufacturers: Distribution by Company Size
Table 39.95 Prefilled Syringe Manufacturers: Distribution by Location of Headquarters
Table 39.99 Global Autoinjectors Market, Historical Trends (2018-2023) (USD Billion)
Table 39.100 Global Autoinjectors Market, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.101 Autoinjectors Market: Distribution by Usability, 2018, 2024 and 2035 (USD Billion)
Table 39.102 Disposable Autoinjectors Market, Historical Trends (2018-2023) (USD Billion)
Table 39.103 Disposable Autoinjectors Market, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.104 Reusable Autoinjectors Market, Historical Trends (2018-2023) (USD Billion)
Table 39.105 Reusable Autoinjectors Market, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.106 Autoinjectors Market: Distribution by Route of Administration, 2018, 2024 and 2035
Table 39.107 Autoinjectors Market for Subcutaneous Administration, Historical Trends (2018-2023) (USD Billion)
Table 39.108 Autoinjectors Market for Subcutaneous Administration, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.109 Autoinjectors Market for Intramuscular Administration, Historical Trends (2018-2023) (USD Billion)
Table 39.110 Autoinjectors Market for Intramuscular Administration, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.111 Autoinjectors Market for Intravenous Administration, Historical Trends (2018-2023) (USD Billion)
Table 39.112 Autoinjectors Market for Intravenous Administration t, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.113 Autoinjectors Market for Subcutaneous / Intramuscular Administration, Historical Trends (2018-2023) (USD Billion)
Table 39.114 Autoinjectors Market for Subcutaneous / Intramuscular Administration, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.115 Autoinjectors Market for Subcutaneous / Intravenous Administration, Historical Trends (2018-2023) (USD Billion)
Table 39.116 Autoinjectors Market for Subcutaneous / Intravenous Administration, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.117 Autoinjectors Market: Distribution by Type of Molecule Delivered, 2018, 2024 and 2035
Table 39.118 Autoinjectors Market for Proteins, Historical Trends (2018-2023) (USD Billion)
Table 39.119 Autoinjectors Market for Proteins, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.120 Autoinjectors Market for Small Molecules, Historical Trends (2018-2023) (USD Billion)
Table 39.121 Autoinjectors Market for Small Molecules, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.122 Autoinjectors Market for Antibodies, Historical Trends (2018-2023) (USD Billion)
Table 39.123 Autoinjectors Market for Antibodies, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.124 Autoinjectors Market for Peptides, Historical Trends (2018-2023) (USD Billion)
Table 39.125 Autoinjectors Market for Peptides, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.126 Autoinjectors Market for Other Molecules, Historical Trends (2018-2023) (USD Billion)
Table 39.127 Autoinjectors Market for Other Molecules, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.128 Autoinjectors Market: Distribution by Type of Actuation Mechanism, 2018, 2024 and 2035 (USD Billion)
Table 39.129 Autoinjectors Market for Automatic Actuation, Historical Trends (2018-2023) (USD Billion)
Table 39.130 Autoinjectors Market for Automatic Actuation, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.131 Autoinjectors Market for Manual Actuation, Historical Trends (2018-2023) (USD Billion)
Table 39.132 Autoinjectors Market for Manual Actuation, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.133 Autoinjectors Market: Distribution by Volume of Container, 2018, 2024 and 2035 (USD Billion)
Table 39.134 Autoinjectors Market for1-2 mL Volume, Historical Trends (2018-2023) (USD Billion)
Table 39.135 Autoinjectors Market for1-2 mL Volume, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.136 Autoinjectors Market for Less than 1 mL Volume, Historical Trends (2018-2023) (USD Billion)
Table 39.137 Autoinjectors Market for Less than 1 mL Volume, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.138 Autoinjectors Market for More than 2 mL Volume, Historical Trends (2018-2023) (USD Billion)
Table 39.139 Autoinjectors Market for More than 2 mL Volume, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.140 Autoinjectors Market: Distribution by Target Therapeutic Indication, 2018, 2024 and 2035
Table 39.141 Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.142 Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.143 Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.144 Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.145 Autoinjectors Market for Diabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.146 Autoinjectors Market for Diabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.147 Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.148 Autoinjectors Market for Anaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.149 Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) (USD Billion)
Table 39.150 Autoinjectors Market for Weight Loss, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.151 Autoinjectors Market for Migraine, Historical Trends (2018-2023) (USD Billion)
Table 39.152 Autoinjectors Market for Migraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.153 Autoinjectors Market for Other Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.154 Autoinjectors Market for Other Indications, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.155 Autoinjectors Market for Home Settings, Historical Trends (2018-2023) (USD Billion)
Table 39.156 Autoinjectors Market for Home Settings, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.157 Autoinjectors Market for Hospitals and Clinics, Historical Trends (2018-2023) (USD Billion)
Table 39.158 Autoinjectors Market for Hospitals and Clinics, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.159 Autoinjectors Market for Ambulatory Surgical Centers, Historical Trends (2018-2023) (USD Billion)
Table 39.160 Autoinjectors Market for Ambulatory Surgical Centers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.161 Autoinjectors Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Table 39.162 Autoinjectors Market for North America, Historical Trends (2018-2023) (USD Billion)
Table 39.163 Autoinjectors Market for North America, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.164 Autoinjectors Market for Europe, Historical Trends (2018-2023) (USD Billion)
Table 39.165 Autoinjectors Market for Europe, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.166 Autoinjectors Market for Asia-Pacific, Historical Trends (2018-2023) (USD Billion)
Table 39.167 Autoinjectors Market for Asia-Pacific, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.168 Autoinjectors Market for Middle East and North Africa, Historical Trends (2018-2023) (USD Billion)
Table 39.169 Autoinjectors Market for Middle East and North Africa, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.170 Autoinjectors Market for Latin America, Historical Trends (2018-2023) (USD Billion)
Table 39.171 Autoinjectors Market for Latin America, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.172 Disposable Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.173 Disposable Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.174 Reusable Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.175 Reusable Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.176 Subcutaneous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.177 Subcutaneous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.178 Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.179 Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.180 Intravenous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.181 Intravenous Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.182 Proteins Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.183 Proteins Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.184 Antibodies Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.185 Antibodies Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.186 Small Molecules Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Historical Trends (2018-2023) (USD Billion)
Table 39.187 Small Molecules Autoinjectors Market for Rheumatoid Arthritis and Psoriatic Arthritis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.188 Disposable Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.189 Disposable Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.190 Reusable Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.191 Reusable Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.192 Subcutaneous Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.193 Subcutaneous Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.194 Intramuscular Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.195 Intramuscular Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.196 Proteins Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.197 Proteins Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.198 Peptides Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.199 Peptides Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.200 Antibodies Autoinjectors Market for Multiple Sclerosis, Historical Trends (2018-2023) (USD Billion)
Table 39.201 Antibodies Autoinjectors Market for Multiple Sclerosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.202 Disposable Autoinjectors Market for Diabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.203 Disposable Autoinjectors Market for Diabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.204 Reusable Autoinjectors Market for Diabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.205 Reusable Autoinjectors Market for Diabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.206 Subcutaneous Autoinjectors Market for Diabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.207 Subcutaneous Autoinjectors Market for Diabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.208 Proteins Autoinjectors Market for Diabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.209 Proteins Autoinjectors Market for Diabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.210 Antibodies Autoinjectors Market for Diabetes, Historical Trends (2018-2023) (USD Billion)
Table 39.211 Antibodies Autoinjectors Market for Diabetes, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.212 Disposable Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.213 Disposable Autoinjectors Market for Anaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.214 Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.215 Intramuscular Autoinjectors Market for Anaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.216 Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.217 Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.218 Small Molecules Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.219 Small Molecules Autoinjectors Market for Anaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.220 Disposable Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) (USD Billion)
Table 39.221 Disposable Autoinjectors Market for Weight Loss, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.222 Subcutaneous Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) (USD Billion)
Table 39.223 Subcutaneous Autoinjectors Market for Weight Loss, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.224 Peptides Autoinjectors Market for Weight Loss, Historical Trends (2018-2023) (USD Billion)
Table 39.225 Peptides Autoinjectors Market for Weight Loss, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.226 Small Molecules Autoinjectors Market for Anaphylaxis, Historical Trends (2018-2023) (USD Billion)
Table 39.227 Small Molecules Autoinjectors Market for Anaphylaxis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.228 Disposable Autoinjectors Market for Migraine, Historical Trends (2018-2023) (USD Billion)
Table 39.229 Disposable Autoinjectors Market for Migraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.230 Subcutaneous Autoinjectors Market for Migraine, Historical Trends (2018-2023) (USD Billion)
Table 39.231 Subcutaneous Autoinjectors Market for Migraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.232 Antibodies Autoinjectors Market for Migraine, Historical Trends (2018-2023) (USD Billion)
Table 39.233 Antibodies Autoinjectors Market for Migraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.234 Proteins Autoinjectors Market for Migraine, Historical Trends (2018-2023) (USD Billion)
Table 39.235 Proteins Autoinjectors Market for Migraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.236 Small Molecules Autoinjectors Market for Migraine, Historical Trends (2018-2023) (USD Billion)
Table 39.237 Small Molecules Autoinjectors Market for Migraine, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Billion)
Table 39.238 Disposable Autoinjectors Market for Other Indications, Historical Trends (2018-2023) (USD Billion)
Table 39.239 Disposable Autoinjector